

from the trials of tamoxifen and raloxifene, particularly NSABP P1 and the MORE trial, respectively, demonstrated the ability of this class of agents to reduce, at least in the short term, the incidence of breast cancer. The large 19,000 patient STAR trial should complete accrual in the near future and provide information on the relative efficacy and, importantly, toxicity of these 2 SERMs.

The third-generation aromatase inhibitors have become established for management of women in the metastatic disease and adjuvant therapy settings. Strong evidence is available from clinical trials for the non-steroidal aromatase inhibitors anastrozole and letrozole in the first-line metastatic setting to choose one of these agents over tamoxifen based on efficacy and tolerability. In the adjuvant setting, two large placebo-controlled trials have been reported which demonstrate substantial reduction in the incidence of contralateral breast cancers with anastrozole (ATAC) and letrozole (MA.17). These findings plus the fact that aromatase inhibitors are associated with a lower incidence of thromboembolism and endometrial pathology than tamoxifen has made them attractive for study in the prevention setting. IBIS II is evaluating anastrozole against placebo and MAP3 will study the steroidal aromatase inhibitor exemestane (with or without celecoxib) against placebo. In the latter trial, the cyclooxygenase-2 inhibitor celecoxib has been selected for study because of preclinical data showing inhibition of both ER-positive and ER-negative breast cancers and value of combining this agent with exemestane. In addition, long-term NSAID use has been associated with decreased breast cancer risk. The implications of profound lowering of estrogens are clear and close evaluation of end organ effects is recognized.

A major problem with the large prevention trials to date is the large patient sample sizes, thus long time and high cost, required. Research is being conducted to evaluate surrogate endpoint biomarkers that would facilitate smaller trials able to be completed in shorter time-frames.

In addition to estrogen action through the estrogen receptor, the generation of genotoxic metabolites of estradiol represents a potential mechanism of breast carcinogenesis. Estrogen genotoxicity represents an area of ongoing investigation with numerous potential therapeutic strategies.

339

INVITED

#### Intraductal techniques in surveillance

J. O'Shaughnessy. U.S. Oncology, Chemoprevention Res. Programme, Dallas, Texas, USA

Atypical hyperplasia develops along the continuum of breast intraepithelial neoplasia (IEN), the genotypic and phenotypic epithelial cell changes that evolve into and accompany invasive cancer, and may be an obligate precursor of invasive breast cancer. Although there are no prospective studies that have evaluated whether high-risk women with cytologically-identified hyperplasia with atypia derive as much benefit from tamoxifen as do women with pathologically defined atypical hyperplasia, many experts believe that the breast cancer risks of both groups are similarly elevated and that tamoxifen treatment is indicated for both. Random, periareolar bilateral breast FNA in women at elevated risk for developing breast cancer on the basis of a family history or an elevated 10-year Gail risk score has been shown to detect breast epithelial cell atypia in 21% of high-risk women. Although nipple aspirate fluid (NAF) can be collected by experienced hands from approximately 60% to 80% of women, cellular yields for cytologic analysis are often low. Ductal lavage has been developed as a minimally invasive way of facilitating retrieval of intraductal epithelial cells to identify women who are at markedly elevated risk of developing breast cancer due to the presence of atypical epithelial cells. The primary purpose of ductal lavage is risk stratification- to provide additional information to women who are at elevated risk on the basis of their 5-year Gail risk score and to distinguish between those who are at elevated versus high risk. In a large study by Dooley, et al., ductal lavage was 3.2 times more sensitive in detecting abnormal cells than was NAF when samples from the same breast were compared. Ductal lavage is an excellent tool for evaluating the effectiveness of new breast IEN treatment agents in high-risk women. Several clinical trials have been initiated or are planned to serially monitor atypical breast epithelial cells in high-risk women who are taking an aromatase inhibitor or a novel investigational risk reduction agent such as celecoxib. Ductal lavage is being used to investigate the molecular characteristics of breast epithelial cells and proteins in ductal lavage effluent. Promising molecular markers under study include LOH of DNA markers, methylated genes, and abnormal protein patterns on mass spectroscopy.

340

INVITED

#### Prophylactic mastectomy in high risk women

J.G.M. Klijn. Erasmus MC, Daniel den Hoed Cancer Center, Medical Oncology, Rotterdam, The Netherlands

Current risk-reduction strategies aimed at prevention of breast cancer and death by cancer include changes in lifestyle, early detection of cancer by

regular surveillance, prophylactic mastectomy (PM), prophylactic oophorectomy (PO) and chemoprevention. Early studies on the possible interest in PM in untested high-risk women showed a wide range of outcomes. At our family cancer clinic 51% of unaffected women with a proven gene mutation choose PM, and 64% PO. Until recently, only case reports and retrospective studies of the outcome of prophylactic mastectomy (mainly subcutaneous, and thus often incomplete) have been published. However, Hartmann and colleagues reported an approximate 90% risk reduction by PM in 639 women with a family history of breast cancer after a median follow-up of 14 years. In a very small group of 18 women with a confirmed BRCA1 or BRCA2 mutation no breast cancers were observed after PM after a median follow-up of 13 years. After these retrospective studies, we performed the first prospective comparative study in 139 BRCA1/2 mutation carriers. No cases of breast cancer were observed after bilateral total PM after a mean follow-up of 2.9 year in 76 BRCA1/2 mutation carriers (mean age 37.7 yr) in contrast to 8 breast cancers in the surveillance group (n=63, mean age 39.5 yr, mean follow-up 3.0 year) resulting in a hazard ratio of 0 (95% CI: 0-0.36; p=0.003). After a recent preliminary update at 5.2 yr of follow-up this risk reduction (92%) was still highly significant (p<0.02), also after adjustment for PO (p<0.03). In our affected BRCA1/2 mutation carriers with primary breast cancer, 35% of the patients opted for prophylactic bilateral/contralateral mastectomy, also resulting in a strong risk reduction for a second primary breast cancer, but till thusfar without a significant effect on overall survival. The strong protective effect of PM must be weighed against possible surgical complications by breast reconstruction, psychological problems and quality of life. In our experience only 5% did regret PM, but at 3 years of follow-up a significant number of women reported some negative effects on body image and sexuality. Endocrine prevention by PO or chemoprevention resulted in a risk reduction of about 50% for breast cancer.

In conclusion: thusfar prophylactic bilateral total mastectomy is the most effective way of prevention, but PO is a reasonable alternative, while chemoprevention has to be preferably applied in clinical trials.

Friday, 19 March 2004

14:15-15:45

#### SYMPOSIUM

### Breast conserving surgery – 30 years of experience

341

INVITED

#### Breast conservation: overview and future perspectives

U. Veronesi. European Institute of Oncology, Milan, Italy

The revolution in breast cancer treatment was ushered in by our work in the 1970s with conservative surgical approach. A randomized trial began in Milan in 1973 to compare small size breast cancer patients treated by Halsted mastectomy (the standard operation till that time) with those receiving breast sparing – quadrantectomy – plus axillary dissection and 50 Gy radiotherapy administered in two tangentially opposed fields using high energy equipment, plus a boost of 10 Gy on the scar with orthovoltage equipment (QUART).

The survival curves showed that QUART gave identical results to Halsted mastectomy, and that subdivision of patients by tumor size, site and age still did not reveal any difference between the treatments.

An important development of conservation surgery refers to the possibility of avoiding axillary dissection when axillary nodes are negative. Although axillary dissection is an important staging procedure, more and more patients present themselves with small carcinomas and all too often axillary dissection reveals only healthy lymph-nodes. We studied the ability of sentinel node biopsy to predict the status of the axilla in order to obtain information on the safety of foregoing axillary dissection when the sentinel node is negative. A randomized trial on the safety and efficacy of sentinel node biopsy was conducted in the years 1998-1999 and the data published in N Engl J Med. We recruited 516 patients, who were randomized between routine total axillary dissection and elective axillary dissection, only in cases where a positive sentinel node biopsy was present. The 5-year rate of local-regional recurrences and survival was not different in the two arms.

In the field of complementary treatments, intraoperative radiotherapy (ELIOT: Electron Intraoperative Therapy) could become one of the other main issues in the management of early breast cancer.

The theoretical gain of the use of ELIOT in the treatment of breast cancer is the delivery of a high dose radiotherapy to a very limited area of the body (and of the breast itself), with a good spare of normal tissues and organs. The incidence of local relapse is in fact higher just in the site of tumour resection, with a much lower probability of relapse in the other quadrants of the same breast.